2Wolff J A, Fisher I J, Xu L, et al. Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease. Proc Natl Acad Sci USA.1989.86:9011-9014.
3Hudson J,Granholm AC ,Gerhardt GA, et al. Glial cell linederived neurotrophic factor augments midbrain depaminergic circuits in vivo. Brain Res Bull,36:425-432.
4Cheng FC , Ni DR, Wu MC, et al. Glial cell line-derived neurotrophic factor protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine ( MPTP)-indrs neurotoxicityin C57BL/6 mice. Neurosci Lett, 1998,25 : 87-89.
5Rosenblad C,Martine ZA,Klund A, et al. Intrast viatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriated dopaminergic afferents and induces recovery of function in a rate model of Parkinson disease. Neuroscience. 1998. 82: 129-137.
6Muramatsu S, Fujlmoto K, Ikeguehl K, et al. Behavioral recovery in a primate model of Parklnson' s disease by trip letransduction of striatal ceus with deno-associated viral vectors expressing dopamine- synthesizing enzymes. Hum Gene Ther,2002, 13: 345-354.
7Fan D, Shen Y, Kang D, et al. Adeno-associated virus vectormediated triple gene transfer of dopamine synthetic enzymes. Chin Med J (Engl), 2001, 114: 1276-1279.
8Mandel RJ, Snyder RO, Left SE. Recombinant Adenoassociated viral vector-mediated glial cell line-derived neurotrophic factor gene tranfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's Disease. Exp Neruo, 1999, 160: 201-214.
9Bankeiwicz KS, Eberling JL, Kohumicka M, et al. Convection-enhanced delivery of AAV vector in Parkinsonian monkeys; In vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neuro,2000, 164: 2-14.
10Reynolds P, Dmitriev I, Curiel D. Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the destribution of transgene expression of the systemically administered vector. Gene Ther,1999, 6 : 1336-1339.
4Mandel RJ,Rendahl KG,Snyder RO,et al.Progress in direct striatal delivery of L-DOPA via gene therapy for treatment of Parkinson's desease using recombinant adeno-associated viral vectors[J].Exp Neurol,1999,159(1):47-64.
5Prasad KN,Clarkson ED,La Rosa FG,et al.Efficacy of grafted immortalized dopamine neurons in an animal model of Parkinsonism:a review[J].Mol Genet Metab,1998,65 (1):1-9.
6Costantini LC,Bakowska JC,Breakefield XO,et al.Gene therapy in the CNS[J].Gene Therapy,2000,7 (2):93-109.
8During MJ,Kaplitt MG,Stern MB,et al.Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation[J].Hum Gene Ther,2001,12 (12):1589-1591.
9Luo J,Kaplitt MG,Fitzsimons HL,et al.Subthalamic GAD gene therapy in a Parkinson's disease rat model[J].Science,2002,298(5592):425-429.
10Hopkins Tanne J.Diet supplements and gene therapy tried for Parkinson's disease[J].BMJ,2002,325(7369):851.
